Detalles de la búsqueda
1.
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Antimicrob Agents Chemother
; 68(2): e0113223, 2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205999
2.
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial.
Antimicrob Agents Chemother
; 67(5): e0141922, 2023 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022196
3.
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
J Antimicrob Chemother
; 78(10): 2471-2480, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37596890
4.
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019).
J Glob Antimicrob Resist
; 26: 117-127, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051400
5.
Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Diagn Microbiol Infect Dis
; 81(2): 112-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25488274
6.
Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
Pharmacotherapy
; 34(3): 240-50, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23926058
Resultados
1 -
6
de 6
1
Próxima >
>>